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illustrated in Figures 1 and 2 are not
generated with the Kaplan–Meier
method, as anybody familiar with
this statistical approach can readily
confirm (eg, no staircase appearance,
both curves end at 5 years in both
figures, symbols are used to differen-
tiate study groups instead of cen-
sored/uncensored data that are not
reported anywhere in the article).
The authors should explain how
they built the curves: in other words,
if they did not use a statistical soft-
ware—as it appears—they must ex-
plain according to what rules they
drew the curves that do not appear
to take into account the difference
between censored and uncensored
data (ie, the foundation of survival
analysis). The reason for the discrep-
ancy between the method cited in the
‘‘Methods’’ section and the figures
shown in the ‘‘Results’’ section
should be explained and the error
corrected.
2. In the text (‘‘Results’’ section), the
median survival appears to be 17.9
and 23.1 months for the elderly and
the younger group of patients, re-
spectively. However, likely because
of the aforementioned issue, the me-
dian survivals extrapolated from the
curves depicted in Figure 1 are strik-
ingly different (roughly 23 and 30
months, respectively). This is further
proof that something is wrong with
the survival analysis reported by
Ruol and colleagues.
3. In the ‘‘Discussion’’ section the au-
thors keep repeating that the study
was specifically designed to investi-
gate the impact of age on the clinical
outcome. Nevertheless, they did not
provide any study design in the
‘‘Methods’’ section. In particular,
they did not specify the power of
the study, which is of paramount im-
portance to correctly interpret their
findings. Since their conclusion is
that no survival difference was de-
tected between the two study groups,
what is the error beta of this analysis?
In other words, what is the likelihood
that the null hypothesis (no differ-
ence between survivals) was incor-
rectly accepted? Or, the other way
around, what is the median survival
difference detectable with the sam-
ple size considered in the study?
4. In the Cox model, the authors chose
to include seven covariates: besides
age, which was the variable specifi-
cally targeted by the study, the
choice of the other variables appears
quite ‘‘random.’’ In fact, if one can
agree on the choice of the variables
resulted significant at the univariate
analysis reported in Table 7 (ie, tu-
mor stage and grading); however,
it is more difficult to understand
why the authors included other non-
significant variables (ie, sex, tumor
location, neoadjuvant therapy, his-
tologic type) while they completely
omitted significant variables, such
as those reported in Table 2 (ie, his-
tory of respiratory disease, history
of vascular disease, and American
Society of Anesthesiologists classi-
fication). Since the number and the
type (informative vs confounding)
of variables included in the model
can profoundly affect the final re-
sult, the authors should explain the
reasons for their choice and provide
data on models built with all the var-
iables yielding significant results at
univariate analysis.
5. In Table 8 (results of the Cox
model), the authors reported the c2
values for each covariate: clearly
this information is meaningless to
most readers, who are certainly
much more interested to know the
hazard ratio associated with each
covariate (ie, the risk of death of
the covariate categories as compared
with the baseline category). Again,
the choice of the authors appears
unfounded and leaves some doubts
on the statistical competence of the
person(s) who took care of the data
analysis.
6. Although there is a significant differ-
ence in preoperative risk (as assessed
by the American Society of Anesthe-
siologists score system) between the
two study groups (Table 2), the post-
operative death rates are almost
identical (Table 6). If confirmed,
this is a potentially useful piece of
information that has been com-
pletely overlooked in the ‘‘Discus-
sion’’ section. If the authors are
confident in their data, they should
probably let the American Society
of Anesthesiologists know that the
most commonly used preoperative
risk assessment score likely does
not work with patients affected
with esophageal cancer.
Overall, I am aware that the above list re-
sembles a second revision rather than a com-
mentary on an article already published. In
this regard, I believe that the review process
in this specific case has failed to detect some
significant limits of the manuscript and thus
the responsibility of such ‘‘limping’’ publi-
cation is not to be attributable only to the au-
thors. On the other hand, I hope everybody
will agree that clinical research cannot be
thought of as a list of therapeutic interven-
tions with approximate data analysis, inas-
much as no scientifically and/or clinically
meaningful information can derive from
such an approach.
If we intend to make advances in medi-
cine (as well as in any other field) by publish-
ing the experiences of research groups in
scientific journals so that other researchers
can take advantage of the published data,
we must guarantee that the information is
at least formally correct.
In this specific case, I would recommend
that the authors have the data analysis
revised by a biostatistician and then publish
a letter with the explanations and corrections
necessary to recover the reliability of their
work.
William Yung, MD
Department of Medical Oncology
University of Alabama at Birmingham
Birmingham, Ala
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Letters to the Editor
The Journal of Thoracic and CardiovascuReply to the Editor:
We appreciate Dr Yung’s concerns about
the quality of scientific articles published
in peer-reviewed journals such as the
Journal of Thoracic and Cardiovascular
Surgery, which are read by thousands of
specialists in both thoracic and general
surgery. It has been a privilege for us
to have our data published in the Journallar Surgery c Volume 135, Number 2 469
Letters to the Editorand we would like to reassure Dr Yung
that the review process of the Journal
has not failed to detect possible signi-
ficant limits in our manuscript, as he
suggested.
We will supply the following details.
1. The survival curves shown in the
figures were generated with the
Kaplan–Meier method, but the ‘‘re-
production’’ process failed to show
the typical staircase appearance.
We are submitting 2 new figures
with the censored numbers (Figures
1 and 2). The P values are the same
because the survival estimate had al-
ready been correctly calculated with
the Kaplan–Meier method.
2. The median survival for all patients
was 29.8 for patients younger than
70 years old and 20.8 for those older.
Once again, nothing was wrong with
the survival analysis we had pro-
vided the readers; it was just a typing
mistake, as anyone truly familiar
with statistics surely has already
realized.
3. We obviously included in the multi-
variate analysis variables significant
on univariate analysis, plus other
variables that, although not signifi-
cant on univariate analysis, the
reader might have been interested
to see in the multivariate analysis
(eg, use of neoadjuvant therapy, his-
tologic type). We did not include
variables of no clinical interest (eg,
region where the patients came
from) but only variables of clinical
interest. We also are providing
a new multivariate analysis that in-
cludes the variables suggested by
Dr Yung. Clearly, pStage, as anyone
could expect, remains the most sig-
nificant factor predicting long-term
survival (Tables 1 and 2).
4. c2 Is not meaningless and there are
hundreds of papers with c2 rather
than hazard ratio. In any case, we
are supplying the data Dr Yung
was interested in (Table 3). Obviously,
and once again, this was clearly not an
issue of statistical ‘‘competence’’ or
‘‘ignorance,’’ but rather preference.
5. We want to reassure Dr Yung (not
the American Society of Anesthesi-
ologists [ASA], which is already
aware of this) that the ASA score
does work for esophageal cancer.470 The Journal of Thoracic and CardioFigure 1. All patients.vaThe fact that mortality rates in youn-
ger and elderly patients are similar
does not necessarily imply that there
cannot be differences in the ASA
class distributions among the
groups. When we analyzed patients
from both groups and compared
mortality and morbidity of patients
in ASA classes I–II versus those inscular Surgery c February 2008ASA classes III–IV, this is what we
learned (Table 4).
The ASA classes do make a difference in
the risk of mortality.
We hope Dr Yung is now pleased with
the completeness of the data provided.
There is definitely no need to ‘‘recover’’
this article. We are sure the reviewers of
the Journal who took care of our—not thatFigure 2. RO patients.
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ASA, American Society of Anesthesiologists.
TABLE 2. Multivariate analysis
HR (95% CI) P value
Age ($70 y) — .26
pStage (III–IV) 2.73 (2.23–3.34) ,.0001
Histologic type (SCC) 1.33 (1.08–1.64) .008
Degree of tumor differentiation (poor) 1.26 (1.01–1.58) .04
ASA class (III–IV) — .19
Respiratory history (yes) 1.39 (1.09–1.77) .008
HR, Hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma; ASA, American Society of
Anesthesiologists.
TABLE 3. Multivariate analysis
HR (95% CI) P value
pStage (III–IV) 2.68 (2.19–3.28) ,.0001
Histologic type (SCC) 1.37 (1.11–1.69) .005
Degree of tumor differentiation (poor) 1.25 (1–1.56) .048
HR, Hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma.
TABLE 4. Mortality data
In-hospital mortality P value 30-day mortality P value
ASA class .006 .002
I–II 8/527 (1.5%) 5/527 (0.9%)
III–IV 11/194 (5.7%) 9/194 (4.6%)
ASA, American Society of Anesthesiologists.The Journal of Thoracic and Cardiovascu‘‘limping,’’ really—manuscript were at least
as precise and meticulous in their work as
Dr Yung would have been. Hypercriticism
for the sake of being critical does not help
any progress in surgical research.





University of Padova School of Medicine
Padova, Italy
doi:10.1016/j.jtcvs.2007.10.018lar Surgery c Volume 135, Number 2 471
